81 results about "Pharmaceutical Dose Form" patented technology

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Methods and apparatus (10) for Raman spectral analysis of a sample (12), such as a pharmaceutical dosage form, are disclosed. Delivery optics (16) are used to deliver probe light to a delivery region (13) on the sample, and collection optics (20) are used to collect, from a collection region (17) on the sample spaced from the delivery region, the probe light following scattering through the sample. Each of a plurality of target Raman spectral features are measured in the collected light, and a spectral distortion of the collected light arising during scattering through the sample is determined. A property of the sample is then quantified using the target Raman spectral features in combination with the determined spectral distortion, such that the quantified property is compensated for the spectral distortion.

There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and / or a volume-based mean diameter, and / or a structural / particle density, that is / are similar to the weight- and / or volume-based mean diameter, and / or the structural / particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and / or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

An oral pharmaceutical dosage form, which is intended to provide the desired retention in an individual on the basis of geometric differences between dosage form states before and after administration. The oral pharmaceutical dosage form comprises swellable and expandable material (5). The material (5), upon swelling or expansion, drives the overall size of the oral pharmaceutical dosage form to expand, thereby allowing the oral pharmaceutical dosage form to remain in the stomach for a desired period of time.

The invention belongs to the technical field of medicine dosage forms, and particularly relates to a conjugated estrogen-progestational hormone double-layer tablet and a preparation method thereof. The preparation method comprises the following steps: performing powder mixing on conjugated estrogen and a first medicine auxiliary material to obtain conjugated estrogen powder; carrying out wet granulation on progestational hormone and a second medicine auxiliary material to obtain progestational hormone granules; and tabletting the conjugated estrogen powder and the progestational hormone particles by using a double-layer tablet press to obtain the conjugated estrogen-progestational hormone double-layer tablet. The conjugated estrogen-progestational hormone double-layer tablet prepared by the invention can simultaneously meet the slow release of conjugated estrogen and the quick release of progestational hormone, so that the medicine taking frequency is reduced, and the compliance of a patient is improved; and meanwhile, the stability of a drug bound with estrogen and the bioavailability of progestational hormone are improved.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and chidaridine.

The present application provides a kind of nintedanib solution for inhalation and preparation method and application, the inhalation solution includes active substance, solvent and auxiliary material, the single dose specification of the inhalation solution is 1-5ml, and the active substance in single dose specification is 2.41-12.04mg / ml nintedanib ethanesulfonic acid;The solvent is sterile injection solution water;The auxiliary material includes isotonicity regulator and pH regulator and can also include antioxidant;The addition amount of the isotonicity regulator is to make the inhalation solution have the weight molal osmotic concentration of 240-400mOsmol / kg;The addition of the pH regulator is to make the pH value of the inhalation solution preparation 3.0-4.0.The inhalation nintedanib solution of the present application can provide a kind of nintedanib for inhalation with convenient, safe and effective, and good stability of drug dosage form and drug delivery system in combination with liquid atomization device.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an ITGA6 inhibitor in preparation of a medicine for treating uveal melanoma. By integrating bioinformatics analysis of databases of TCGA, GTEx, CPTAC and the like, the invention systematically reveals that the ITGA6 has high specific expression in uveal melanoma and is significantly related to poor prognosis of a patient for the first time. In-vitro experiments prove that by knocking down ITGA6, proliferation, migration, invasion and colony forming ability of UVM cells can be effectively inhibited. According to the invention, small molecular compounds such as 4.5-diphenyl-1H-imidazole, MS-275, W-13 and the like and siRNA (small interfering Ribonucleic Acid) targeting ITGA6 are screened out to be used as effective inhibitors, and specific drug dosage forms such as intraocular injection and the like are provided. In addition, the ITGA6 inhibitor can be used in combination with a PD-1 / PD-L1 inhibitor, a CTLA-4 inhibitor or a chemotherapeutic drug to generate a synergistic anti-tumor effect. Mechanism research shows that ITGA6 promotes UVM progress by regulating a signal channel and a tumor immune microenvironment. The invention provides a new targeted treatment strategy for uveal melanoma, and has important clinical application value.

The present invention relates to a solid pharmaceutical dosage form for oral administration, comprising (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32, 5-dioxo-14-(trifluoromethyl)-32H-6-aza-3 (4, 1)-pyridine-1 (1)-[1, 2, 3] triazole-2 (1, 2), 7 (1)-dibenzaheptaphane-74-carboxamide (active ingredient (I)), and a pharmaceutically acceptable salt thereof. The active ingredient (I) is present in amorphous form and is released immediately from a solid pharmaceutical dosage form for oral administration, and to a method for the production thereof, to the use thereof as a medicament, and to the use thereof for the treatment and / or prophylaxis of diseases, in particular diseases, such as diseases. Use in particular for cardiovascular disorders, preferably thrombotic or thromboembolic disorders and oedema and ocular disorders

The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising(i) levodopa in an amount ranging from 50 mg to 300 mg,(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically equivalent amount of another aromatic amino acid decarboxylase inhibitor, and(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the proportion of entacapone to carbidopa in said dosage form ranges from 0.3:1.0 to 3.2:1.0 by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight. Pharmaceutical dosage form used in said method are also disclosed.

The present disclosure generally relates to the use of polyvinyl alcohol (PVA) in additive manufacturing technologies and techniques. More specifically, the present disclosure relates to the use of PVA in a selective laser sintering (SLS) method to additively manufacture an object, in particular a pharmaceutical dosage form.

The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof that inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Sustained-release oral pharmaceutical compositions comprising the pharmaceutical composition are described, as well as sustained-release injectable pharmaceutical compositions comprising the pharmaceutical composition.The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal administration comprising the pharmaceutical composition. Also described are: methods for evaluating the efficacy of the pharmaceutical composition; methods for evaluating the inhibitory or partial inhibitory activity of the pharmaceutical composition; methods for treating, alleviating, or preventing a condition or disease comprising administering a therapeutically effective amount of the pharmaceutical composition to a subject; and the use of the pharmaceutical composition for manufacturing a pharmaceutical dosage form for the treatment of a disease.

The invention concerns an orally administrable pharmaceutical dosage form configured for targeted delivery to the distal part of the gastrointestinal tract of a human subject, wherein the pharmaceutical dosage form comprises lanthanum or a pharmaceutically acceptable salt or oxide thereof. The invention further relates to the pharmaceutical dosage form for use in the treatment of hyperoxaluria in a human subject, optionally wherein the hyperoxaluria is primary hyperoxaluria or secondary hyperoxaluria; and / or for use in the treatment of one or more of nephrolithiasis, nephrocalcinosis, or oxalosis in a human subject.

The invention relates to a pharmaceutical dosage form for oral administration comprising (i) an intragranular phase, which comprises Sertraline or a physiologically acceptable salt thereof; one or more intragranular fillers (preferably selected from one or more sugar alcohols or sugars; preferably mannitol or lactose, more preferably mannitol); one or more intragranular antioxidants (preferably selected from butylated hydroxytoluene (BHT), butylated hydroxy anisole (BHA), tocopherol or derivatives thereof, ascorbic acid or derivatives thereof, sodium metabisulphite, propyl gallate, sodium thiosulphate, or any combination thereof, more preferably ascorbic acid); (ii) an extragranular phase, which comprises one or more extragranular fillers (preferably mannitol, microcrystalline cellulose, lactose, or any combination thereof); and (iii) optionally, a film coating. The invention further relates to a process for manufacture by wet granulation, wherein the antioxidant is preferably dissolved in the granulation liquid.

Methods and apparatus (10) for Raman spectral analysis of a sample (12), such as a pharmaceutical dosage form, are disclosed. Delivery optics (16) are used to deliver probe light to a delivery region (13) on the sample, and collection optics (20) are used to collect, from a collection region (17) on the sample spaced from the delivery region, the probe light following scattering through the sample. Each of a plurality of target Raman spectral features are measured in the collected light, and a spectral distortion of the collected light arising during scattering through the sample is determined. A property of the sample is then quantified using the target Raman spectral features in combination with the determined spectral distortion, such that the quantified property is compensated for the spectral distortion.

The invention relates to a pharmaceutical dosage form filled with formulations for once-a-day oral administration of deferiprone and deferasirox. Both formulations are in form of coated pellets or coated minitablets. The invention is directed to the claimed pharmaceutical dosage form for use in the treatment of diseases which cause an overload of iron.

The present invention is to provide an amorphous solid dispersion comprising elacestrant dihydrochloride of formula (I), in combination with one or more pharmaceutically acceptable excipients such as a stabilizing agent including a polymer and / or an alkalizing agent. Additionally, the invention provides a process for the preparation of such amorphous solid dispersions and an amorphous form of elacestrant dihydrochloride. The resulting amorphous form or amorphous solid dispersions are advantageous for the formulation of pharmaceutical dosage forms and compositions, enhancing the bioavailability and stability of elacestrant dihydrochloride.

The utility model discloses a multifunctional medicine dividing device, which relates to the technical field of medical assistance and comprises a crushing box, a liquid dividing mechanism is arranged on one side of the crushing box, a medicine cutting mechanism is arranged on one side of the liquid dividing mechanism, a storage mechanism is arranged on one side of the medicine cutting mechanism, and the crushing box comprises a box body. And a feeding opening is formed in the top of the box body, and a medicine guiding plate is fixedly connected to the surface of the feeding opening. According to the utility model, the crushing box, the box body, the medicine guide plate, the feeding hole, the crushing roller, the inclined plate, the sliding plate, the powder storage box and the medicine pouring hole are matched, the motor drives the crushing roller to crush solid medicines, and the powder is subpackaged after being formed, so that accurate metering and taking are facilitated, the risk of adverse reaction possibly caused by inaccurate dosage is reduced, and the working efficiency is improved. The medicine is convenient for patients to take, avoids the taking difficulty caused by overlarge dosage form or difficulty in accurately segmenting the dosage, and is beneficial to improving the safety and effectiveness of medicine treatment.

The present invention relates to a water-soluble film containing mometasone furoate, adjusted to a pH in the range of 3.5 to 5.0. Adjusting the pH improves the stability of the active ingredient without significantly affecting the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing such films in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can be used, in particular, for the treatment of eosinophilic esophagitis.

In some aspects, the present disclosure relates to drug dosage forms designed to provide a desired retention in an individual based on the geometric difference between the dosage form's pre-administration state and post-administration state. In certain aspects, oral drug dosage forms are provided that include a swellable and expandable material configured to, upon swelling or expansion, promote expansion of the oral drug dosage form's overall size so that the oral drug dosage form is retained in the stomach for a desired period of time. In certain other aspects, the present disclosure relates to components useful in the oral drug dosage forms taught herein. In certain other aspects, the present disclosure relates to design methods, manufacturing methods including three-dimensional (3D) printing, injection molding, ultrasonic welding, or any combination thereof, commercial batches, and methods of delivering a drug to an individual, including administering the oral drug dosage forms taught herein.

A tamper resistant drug dosage is described. The drug dosage form includes a matrix polymer, a scaffold polymer, and a therapeutic agent, and the porosity of the drug dosage form is less than 10%. Methods for making and using the tamper resistant drug dosage forms are described.

The present disclosure provides an amorphous solid dispersion (ASD) comprising an amorphous form of ebselen. Also provided are pharmaceutical compositions and pharmaceutical dosage forms including the subject amorphous solid dispersion. Also provided are methods of delivering the subject ebselen pharmaceutical dosage forms to a subject to achieve an enhanced maximum blood plasma concentration (Cmax) for ebselen with respect to a control ebselen formulation, and an area under the curve (AUC) for both ebselen and an ebselen metabolite that is greater than that achieved with a control ebselen formulation.

Disclosed herein are materials, articles of manufacture, and methods for reducing, mitigating, or precluding formation of and / or amount of a nitrosating agent and / or an N-nitroso compound, including an N-nitrosamine, from a packaging containing an active agent and a pharmaceutical dosage form in an enclosure, wherein the active agent is effective to reduce mitigate or preclude the formation and / or amount of a nitrosating agent and / or N-nitroso compound in the enclosure and / or in the pharmaceutical dosage form. Provided are drug delivery systems comprising a blister pack configured to house multiple pharmaceutical dosage forms, the blister pack comprising an active ingredient that is effective to reduce, mitigate or preclude the formation and / or amount of a nitrosating agent and / or N-nitroso compound in an enclosure of the blister pack and / or in the pharmaceutical dosage form.

The invention discloses hollow adhesive microspheres loaded with rebamipide as well as a preparation method and application of the hollow adhesive microspheres, and belongs to the technical field of improvement of pharmaceutical dosage forms. The preparation method of the rebamipide-loaded hollow adhesive microspheres comprises the following steps: mixing ethyl cellulose, an acrylic resin material and rebamipide in a mixed solvent prepared from a chloralkane solvent and an alcohol solvent to obtain an oil phase solution; mixing polyvinyl alcohol and an oil-in-water surfactant in water to obtain a water phase solution; adding the oil phase solution into the water phase solution, mixing and volatilizing under a stirring condition, and forming a porous cavity structure with a fiber interpenetrating network through liquid-liquid phase separation in a stirring process, so as to obtain the rebamipide hollow microspheres; and carrying out adhesion coating on the rebamipide hollow microspheres to obtain the rebamipide-loaded hollow adhesion microspheres. The rebamipide-loaded hollow adhesive microspheres prepared by the invention can be detained in the stomach for a long time to realize controllable release, so that the bioavailability and the treatment effect of rebamipide are improved.

The invention relates to the technical field of pharmaceutical preparations, and discloses a dipyridamole solid dispersion, a pharmaceutical preparation and a preparation method, the dipyridamole solid dispersion comprises dipyridamole, an enteric material and a plasticizer, and the mass of the enteric material is 65-75% of the total mass of the dipyridamole solid dispersion. The dipyridamole solid dispersion comprises dipyridamole, an enteric-coated material and a plasticizer, dipyridamole is dispersed in the enteric-coated material in an amorphous molecule form, the dissolution rate of dipyridamole in a medium-high pH environment can be remarkably increased, the problem that dipyridamole is difficult to dissolve in an intestinal alkaline environment is effectively solved, and the dipyridamole solid dispersion is suitable for large-scale industrial production. And the oral bioavailability of the dipyridamole is improved. Besides, the dipyridamole solid dispersion and pharmaceutically acceptable auxiliary materials are used as raw materials to prepare the pharmaceutical preparation, so that the pharmaceutical dosage form of the dipyridamole is widened, the oral compliance of the medicine can be improved, and the dipyridamole pharmaceutical preparation is simple, easy to implement, easy to industrially produce and high in application value.

Disclosed herein are materials, articles, and methods for reducing, mitigating, or excluding the formation and / or amount of nitrosylating agents and / or N-nitroso compounds, including N-nitrosamines, in a package containing an active agent and a pharmaceutical dosage form in a shell, wherein the active agent can be effective to reduce, mitigate, or exclude the formation and / or amount of nitrosylating agents and / or N-nitroso compounds in the shell and / or in the pharmaceutical dosage form. There is provided a drug delivery system comprising a blister pack configured to contain a plurality of drug dosage forms, the blister pack comprising an active ingredient, the active ingredient may be effective to reduce, mitigate, or exclude the formation and / or amount of nitrosylating agents and / or N-nitroso compounds in the outer shell of the blister pack and / or in the pharmaceutical dosage form.

The present invention is inter alia concerned with (i) a combination of a CBP / p300 bromodomain inhibitor and a KRAS inhibitor for use in the treatment of a patient suffering from cancer, wherein the cancer exhibits an oncogenic alteration in the KRAS; (ii) a kit comprising (a) a pharmaceutical dosage form comprising a CBP / p300 bromodomain inhibitor and (b) a pharmaceutical dosage form comprising a KRAS inhibitor, and (iii) a pharmaceutical dosage form comprising a CBP / p300 bromodomain inhibitor and a KRAS inhibitor.

The present invention relates to a pharmaceutical dosage form for application to a mucous membrane, in particular to a buccal, intestinal, rectal or vaginal mucous membrane, comprising at least one string-like or strip-like preparation comprising the active pharmaceutical ingredient, the dosage from being configured to be wettable during a step of administration to a patient. The invention also relates to a method of producing the pharmaceutical dosage form.

The present application relates to a pharmaceutical dosage form and a method for preparing the same, such as a pharmaceutical dosage form prepared by a three-dimensional printing method. A pharmaceutical dosage form loaded with a liquid or semi-solid material and a pharmaceutical dosage form loaded with a solid material are both provided.